There are generic Arixtra (fondaparinux) products available for use at this time. All generic Arixtra dosages are now available and are being produced by two different companies, Apotex Corp. and Dr. Reddy's Laboratories, Inc.
Arixtra® (fondaparinux sodium) is a prescription medication used to treat and prevent blood clots. It was the first medication in a class of drugs known as factor Xa inhibitors. It is taken as a once-daily injection just under the skin (a subcutaneous injection).
Brand-name Arixtra is made by GlaxoSmithKline. However, generic forms are available at this time and are approved for use in the United States.
Apotex Corp. and Dr. Reddy's Laboratories, Inc., are currently the only manufacturers of the generic version of Arixtra. Generic fondaparinux sodium is now available in the following strengths:
- Fondaparinux sodium 2.5 mg/0.5 mL prefilled syringes
- Fondaparinux sodium 5 mg/0.4 mL prefilled syringes
- Fondaparinux sodium 7.5 mg/0.6 mL prefilled syringes
- Fondaparinux sodium 10 mg/0.8 mL prefilled syringes.
All generic medications must undergo certain tests to compare them to brand-name medications. The U.S. Food and Drug Administration (FDA) then looks at these tests to decide if the generics are equivalent to the brand-name medications and assigns a rating to each one.
An "AP" rating means that the FDA has determined that a generic medication is equivalent to a brand-name medication. Generic fondaparinux has an "AP" rating, which means it should be equivalent to Arixtra.
However, generic medications are allowed to have different inactive ingredients than the brand-name medication. This might include fillers, dyes, or other ingredients that may cause problems for people with allergies or sensitivities.